11月6日,癌症检测制造商精密科学公司(EXAS)盘中股价大跌近30%,引发市场广泛关注。这一重挫和公司发布的糟糕财报数据以及下调的收入指引不无关系。
具体来看,精密科学公司公布的2024财年第三季度营收实际达到7.09亿美元,低于市场预期的7.177亿美元。更为重要的是,公司大幅下调了2024年全年收入指引。其中将全年收入预期从之前的28.1亿美元至28.5亿美元,下调至27.3亿美元至27.5亿美元;同时将旗下核心筛选部门的收入预期从之前的21.6亿美元至21.8亿美元,下调至20.8亿美元至21亿美元。
上述收入预期的大幅下调引发了市场对公司未来收入增长前景的担忧,成为股价重挫的主因。尽管公司表示计划在2025年加速增长,公司长期前景依然强劲,但投资者显然对眼前的收入放缓表示失望。在业绩承压的背景下,精密科学的股价遭遇了重挫。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.